Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration. Regentis Biomaterials Ltd. (NYSE American: RGNT) is targeting this multi-billion-dollar market with its product Gelrin C, a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows.
Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C is a 10-minute procedure that uses an off-the-shelf hydrogel to support cartilage repair. With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is positioning Gelrin C as a practical regenerative solution for providers, payers and patients.
What begins as a localized cartilage defect can ultimately evolve into a significant clinical and economic challenge. Unlike many tissues in the body, articular cartilage has little ability to regenerate on its own, leaving untreated lesions vulnerable to progressive deterioration that may culminate in osteoarthritis. The economic burden is substantial, with a $15 billion spending gap related to knee OA treatment.
Advances in regenerative medicine are creating new opportunities to address cartilage damage more effectively and efficiently. Regentis’ Gelrin C represents a shift toward simpler, more accessible treatments that can be integrated into standard surgical procedures without the need for cell harvesting or specialized lab work.
For investors, the company’s focus on a large addressable market and a product that addresses unmet clinical needs makes it noteworthy. The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT.
This content was disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid marketing engagement with IBN. IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN. Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
